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Abstract: Currently, the majority of cell-based studies on neurodegeneration are carried out
on two-dimensional cultured cells that do not represent the cells residing in the complex
microenvironment of the brain. Recent evidence has suggested that three-dimensional (3D) in vitro
microenvironments may better model key features of brain tissues in order to study molecular
mechanisms at the base of neurodegeneration. So far, no drugs have been discovered to prevent or
halt the progression of neurodegenerative disorders. New therapeutic interventions can come from
phytochemicals that have a broad spectrum of biological activities. On this basis, we evaluated the
neuroprotective effect of three phytochemicals (sulforaphane, epigallocatechin gallate, and plumbagin)
alone or in combination, focusing on their ability to counteract oxidative stress. The combined
treatment was found to be more effective than the single treatments. In particular, the combined
treatment increased cell viability and reduced glutathione (GSH) levels, upregulated antioxidant
enzymes and insulin-degrading enzymes, and downregulated nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase 1 and 2 in respect to peroxide-treated cells. Our data suggest that
a combination of different phytochemicals could be more effective than a single compound in
counteracting neurodegeneration, probably thanks to a pleiotropic mechanism of action.
Keywords: neurodegeneration; SH-SY5Y cell line; 3D cultures; oxidative stress; phytochemicals;
antioxidants
1. Introduction
Oxidative stress is strongly involved in the pathogenesis of different neurodegenerative diseases
like Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis [1]. Particularly,
an excess of reactive oxygen species (ROS) released by cells promotes oxidative stress, which is a cause
of tissue injury and results in dysfunction in the nervous system. So far, no drugs have been discovered
to prevent or halt the progression of these widely spread neurological disorders, and the treatments
available only manage the symptoms. Therefore, there is an urgent need for new treatments for
these diseases, since the World Health Organization (WHO) predicts that by 2040, neurodegenerative
diseases will become the second-most prevalent cause of death [2]. New therapeutic approaches can
derive from phytochemicals, a huge source of compounds that have been widely investigated in the
last years [3]. Sulforaphane (SF) (Figure 1a) is an isothiocyanate derived from Brassicae vegetables and
has consistent support in the literature for its preventive role against oxidative stress [4], in addition to
its well-known role in chemoprevention [5]. Epigallocatechin gallate (EGCG) (Figure 1b), the major
catechin found in green tea [6] with diverse medical potential [7] has been demonstrated to promote
neuroprotection in numerous studies [8]. Plumbagin (PB) (Figure 1c), a naphthoquinone isolated
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from the Plumbaginacae family, has mainly been studied in respect to its anti-inflammatory [9–11] and
antimicrobial activities [12], even though it was also shown to modulate oxidative stress response [13]
and precisely target NADPH oxidase 4 (NOX4) [14]. Importantly, the treatment of undifferentiated
SH-SY5Y cells with a specific concentration of SF [15], EGCG [16], and PB [17] has been reported to
decrease oxidative stress at different levels. On this basis, we hypothesized that a proper combination
of such bioactive compounds could possess a higher effect in counteracting oxidative stress-induced
neurodegeneration. Within organs, there are various concentration gradients for oxygen as well as for
effector molecules, i.e., internal metabolites or exogenous compounds/drugs. Since the human brain
cannot be modelled adequately in animals [18], reductionist humanized cellular systems are used and
increasingly requested according to the 3Rs (Replacement, Reduction and Refinement) rule.
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Currently, the majority of cell-based studies on neurodegeneration have been carried out on
cultured cells propagated in two dimensions on plastic surfaces. However, cells cultured in these
non-physiological conditions do not represent the cells residing in the complex microenvironment
of the brain. With respect to this, recent evidence has suggested that three-dimensional (3D) in vitro
microenvironments may better model key features of br in tissues in order to study the molecular
mechanisms at the base of neurodegeneration and neurorepair [19,20]. Nu ro s in vitro appr aches
have been carried out to mimic hu an neuronal features, bas d on neuronal-like cells such as
the neuroblastoma line SH-SY5Y. SH-SY5Y is a human cell line that divides qui kly an has the
ability to differentiate in post-mitotic neurons, thus it is considere a convenient model to study
Parkinson’s [21] and Alzheimer’s diseases [22]. Unlike traditional two-dimensio al (2D) cultures,
the different availability of oxygen and growth factors in a 3D cell culture should expectantly favor a
more in vivo-like morphology and growth of these cells. Indeed, several 3D culture models have been
developed with SH-SY5Y cells, in terms of cell aggregates [23], spheroids [24,25], or including different
scaffolds [26–28]. To support 3D cultures of SH-SY5Y or neuronal cell lines, collagen has also been used,
like collagen hydrogel [29] or porous collagen-based scaffolds [26,30]. To the best of our knowledge,
none of the previous models has been used to investigate the ability of natural bioactive molecules to
confer resistance to oxidative stress. The aim of this study was to evaluate the neuroprotective effect of
a combination of SF, EGCG, and PB in preventing cell damage derived from oxidative stress in a 3D
cell culture based on a collagen porous scaffold.
2. Materials and Methods
2.1. Cell Culture and Treatment
The SH-SY5Y human neuroblastoma cell line was obtained from Sigma-Aldrich (cat. n◦ 94030304)
(St. Louis, MO, USA). Cells were expanded in a growth culture medium composed of high glucose
Dulbecco’s Modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS),
2 mM glutamine, 50 U/mL of penicillin, and 50 µg/mL of streptomycin, and cultured at 37 ◦C with
5% CO2 as previously reported [31]. Cell differentiation was induced by reducing serum levels of
the medium to 1% with 10 µM retinoic acid (RA) for seven days prior to treatments [32]. SF (LKT
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Laboratories, Minneapolis, MN, USA), EGCG and PB (Sigma-Aldrich, St. Louis, MO, USA) were
dissolved in DMSO, and 10 mM stocks were kept at −20 ◦C until use. Differentiated SH-SY5Y cells
were treated with 1 µM SF, 2.5 µM EGCG, and 0.5 µM PB and SEP (1 µM SF + 2.5 µM EGCG + 0.5 µM
PB,) for 24 h or 6 h according to the different experiments. Oxidative stress was induced, as previously
reported [33], by exposing cells to 700 µM H2O2 in 1% FBS DMEM.
2.2. 3D Model Preparation
To obtain the scaffolds for 3D cultures of SH-SY5Y cells, sterile heterologous native lyophilized
collagen type I sponge (BIOPAD™, Angelini Pharma Inc., Gaithersburg, USA) was cut using a sterile
scalpel into pieces with squared dimensions able to fit 96-multiwell culture plates. Each piece was
divided by subjecting it to a second longitudinal cut, performed in order to present a similar top surface
as the cells. The pieces with approximately 1 cm2 of surface area were inserted into a 24-multiwell
plate and constituted the scaffolds for the cell culture. To establish the 3D SH-SY5Y culture, 50 µL of
cell suspension in DMEM with 10% FBS was seeded atop of each scaffold. Different cell numbers per
scaffold (50× 103–100× 103–200× 103) were seeded to compare cell viability along the culture (1–6 days)
and optimize cell seeding for differentiation. To differentiate 3D SH-SY5Y culture, a concentration of
4 × 106 cells/mL equivalent to 200 × 103 cells in 50 uL was used. After 45 min of incubation at 37 ◦C,
5% CO2, DMEM with 1% FBS, and 10 µM RA were added to the 3D culture in order to induce cell
differentiation. The medium was changed every two days.
2.3. MTT Assay
Before adding 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), 3D cultures
were transferred to clean cell culture wells. MTT 0.5 mg/mL was prepared in a cell medium and added
to the 3D cultures. To measure the percentage of cells that did not attach to the scaffold, MTT was
also added to the wells where cells were initially seeded (Figure S1). The MTT solution was incubated
for 2 h at 37 ◦C, 5% CO2. After removing the MTT solution, DMSO was added and the absorbance
of formazan was measured at 595 nm using a microplate spectrophotometer VICTOR3 V Multilabel
plate-reader (PerkinElmer, Wellesley USA). The sum of the two respective absorbance values, the first
deriving from the primary wells used during the seeding and the second deriving from the scaffolds,
were considered as 100%.
2.4. Prestoblue Assay
A Prestoblue® working solution was prepared in a growth culture medium without phenol red
according to the manufacturer’s instructions. Briefly, the culture medium was removed from cell
culture wells and a Prestoblue working solution was added and incubated at 37 ◦C, 5% CO2. After 3 h,
the well volumes were collected in a new 96-well plate and the absorbance was read at λ = 570 nm
(experimental) and λ = 600 nm (reference wavelength for normalization) using a Victor Multilabel
plate-reader (Perkin-Elmer, Wellesley USA).
2.5. Reduced Glutathione (GSH) Level Measurement
A monochlorobimane (MCB) fluorescent probe (Sigma-Aldrich, St. Louis, MO, USA) was used
to determine relative intracellular GSH levels as previously reported [34] with some modifications.
After 24 h of treatment, the cell culture medium was removed from 3D samples and the scaffolds were
transferred to 1.5 mL tubes. The cells were incubated for 15 min in DMEM with 1% FBS containing
50 µM MCB, and for a further 15 min in DMEM with 0.5 mg/mL collagenase I and 50 µM MCB
(Sigma-Aldrich). Cells collected by digestion of the scaffold were centrifuged at 250× g. Cells were
resuspended in phosphate-buffered saline (PBS) and plated on black 96-well plates. The fluorescence
was measured at 355 nm (excitation) and 460 nm (emission) using a Victor Multilabel plate-reader
(Perkin-Elmer, Wellesley USA). GSH levels were normalized on the base of the Crystal Violet (CV) assay.
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2.6. Crystal Violet Assay
Crystal Violet (CV) staining was performed as follows: Cells were fixed in 50% MeOH-PBS for 3 h
at 4 ◦C. For 15 min at room temperature, a 0.1% (m/v) CV, 5% MeOH staining solution was incubated.
The staining solution was removed and the stained cells were washed with distilled water. The plate
was left to dry for 5 min under a chemical hood. The bound dye was eluted with MeOH 100% for
30 min at 4 ◦C. The optical density of each well was measured at 570 nm using a Victor Multilabel
plate-reader (Perkin-Elmer, Wellesley USA).
2.7. RNA Extraction and Real-Time PCR
Prior to RNA extraction, cell retrieval was performed by digesting the collagen scaffold in
collagenase solution. Collagenase type I (Sigma-Aldrich) was dissolved in DMEM without FBS at
a concentration of 0.5 mg/mL. Samples were incubated in collagenase solution for 10 min at 37 ◦C.
Cells suspension was pelleted, and RNA was extracted with an RNeasy® mini kit (Qiagen) following
the manufacturer’s instruction. A total of 500 ng of RNA was used to obtain cDNA using an iScript™
cDNA Synthesis Kit (BioRad). Real-time PCR was performed using SsoAdvanced Universal SYBR
Green Supermix (BioRad), and normalized expression levels were calculated relative to control cells
according to the 2−∆∆CT method. Primers were purchased from Sigma-Aldrich. The sequences are
listed in Table 1.
Table 1. Primer sequences.
Gene Sequence RefSeq Accession n.
RPS18 *
Fw CAGAAGGATGTAAAGGATGG
NM_022551
Rv TATTTCTTCTTGGACACACC
MAP2
Fw GAAGATTTACTTACAGCCTCG
NM_002374
Rv GGTAAGTTTTAGTTGTCTCTGG
BDNF
Fw CAAAAGTGGAGAACATTTGC
NM_001143811
Rv AACTCCAGTCAATAGGTCAG
HMOX1(HO1) Fw CAACAAAGTGCAAGATTCTG NM_002133.2
Rv TGCATTCACATGGCATAAAG
IDE
Fw CAACCTGAAGTGATTCAGAAC
NM_001165946
Rv AATATGTGGTTTCACAAGGG
NOX1
Fw CCGGTCATTCTTTATATCTGTG
NM_007052
Rv CAACCTTGGTAATCACAACC
NOX2
Fw AAGATCTACTTCTACTGGCTG
NM_000397
Rv AGATGTTGTAGCTGAGGAAG
NQO1 Fw AGTATCCACAATAGCTGACG NM_000903
Rv TTTGTGGGTCTGTAGAAATG
GSR (GR) Fw GACCTATTCAACGAGCTTTAC NM_000637
Rv CAACCACCTTTTCTTCCTTG
TXNRD1 (TR) Fw AGACAGTTAAGCATGATTGG NM_001093771
Rv AATTGCCCATAAGCATTCTC
* reference gene.
3. Results
3.1. Development and Characterization of the 3D SH-SY5Y Culture System
To fully assess biocompatibility between the collagen scaffold and SH-SY5Y cells, we evaluated
cellular retention to the scaffold and cellular metabolism during 3D culture. The ability of SH-SY5Y
cells to attach to the scaffold was evaluated by an MTT viability assay (Figure 2a). This assay was
chosen because cells convert MTT to blue formazan that is retained by the cells and, for this reason,
it makes it possible to distinguish cells attached to the scaffold from those released from the scaffold
(see Figure S1). As reported in Figure 2a, about 95% of the total viable cells were able to attach after
the switch from 2D to 3D culture conditions, while only 5% of the cells grew outside of the scaffold.
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To check the proliferation of SH-SY5Y cells, we used a Prestoblue assay as it makes it possible to monitor
the metabolic activity of the same cell culture over time (Figure 2b). Cells were seeded at different
concentrations, and cell viability was evaluated after 1 and 6 days. As expected, cell viability increased
with an increasing numbers of cells per scaffold at both time points. Interestingly, the metabolic activity
of the 3D culture after 6 days was comparable to that measured after 1 day at all tested seeding densities.
Because the scaffold did not allow us to observe the cells under a microscope during growth, to verify
that RA-treated SH-SY5Y cells were able to differentiate, we evaluated the mRNA level of the mature
neural protein marker MAP2 as well as the secretable neurotrophin BDNF in 3D RA-treated cells
(Figure 2c). Interestingly, both markers were upregulated in 3D RA-treated cells in respect to the 3D
RA-untreated control, showing their ability to differentiate under 3D culture conditions. Figure S4
reports the macroscopic and microscopic appearance of the 3D SH-SY5Y culture.
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Figure 2. Characterization of the 3D SH-SY5Y model. (a) Cellular adhesion to the scaffold was evaluated
24 h after cell seeding by MTT assay as reported in Materials and Methods. Data are expressed as a
percentage of total viable cells and represent the mean of three independent experiments. (b) Metabolic
activity of the 3D model was evaluated after 1 and 6 days from cell seeding by a Prestoblue assay
as reported in Materials and Methods. Each bar represents the mean ± SEM of three independent
experiments. Data were analyzed with a two-way ANOVA followed by the Fisher’s test. * p < 0.05.
(c) Real time-PCR was performed in the 3D culture for neuronal markers. Each bar represents the mean
± SEM of three independent experiments, which were analyzed with an unpaired T-test. * p < 0.05.
3.2. SF, EGCG and PB Protect 3D SH-SY5Y Cells from Oxidative-Ind ced Injury
Before studying the neuroprotective effect of SF, EGCG, and PB, we exposed 3D differentiated
SH-SY5Y cells to 1 µM SF, 2.5 µM EGCG, 0.5 µM PB, or to a combination of the three compounds at
the same concentrations (SEP) (Figure 3). These concentrations were chosen according to previous
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reports where these concentrations were not very effective against oxidative stress [15–17]. Our results
showed that all the tested concentrations—1 µM SF, 2.5 µM EGCG, and 0.5 µM PB—were not toxic.
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Figure 3. Potential cytotoxicity of sulforaphane (SF), epigallocatechin gallate (EGCG), and plumbagin
(PB) on SH-SY5Y cells. Cells were treated with 1 µM SF, 2.5, µM EGCG, and 0.5 µM PB, and after
24 h, viability was evaluated by a Prestoblue assay as reported in Materials and Methods. Results are
expressed as a percentage of untreated cells. Each bar represents the mean ± SEM of three independent
experiments, which were analyzed with a one-way ANOVA followed by the Fisher’s test.
We then investigated the potential protective effect of the single treatments or a combination of
them against H2O2-induced oxidative stress (Figure 4). As expected, incubation with 700 µM H2O2
for 2 h induced a significant reduction of cell viability compared to the control cells (Figure S2). Only
0.5 µM PB, 1 µM SF, and the co-treatment (1 µM SF, 2.5 µM EGCG, and 0.5 µM PB) were able to protect
the cells against H2O2-induced damage. Of note, SEP co-treatment was the most effective treatment as
it significantly increased cell viability compared to the other treatments.
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Figure 4. Neuroprotective activity of SF, EGCG, and PB compounds against H2O2-induced damage.
Cells were treated with 1 µM SF, 2.5 µM EGCG, and 0.5 µM PB, and after 24 h, were exposed to 700 µM
H2O2 to induce oxidative stress. Cell viability in 3D cultures was measured by a Prestoblue assay as
reported in Materials and Methods. Data are expressed as a percentage of untreated cells. Each bar
represents mean ± SEM of three independent experiments. Data were analyzed with a one-way
ANOVA followed by the Fisher’s test. * p < 0.05 vs. H2O2 treated cells; § p < 0.05 vs. sulforaphane,
epigallocatechin gallate, and plumbagin (SEP) co-treatment.
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3.3. SEP Co-Treatment Enhances Antioxidant Defenses
As our results showed a higher neuroprotective activity of SEP co-treatment (1 µM SF, 2.5 µM
EGCG, and 0.5 µM PB) compared to the single treatments of 1 µM SF, 2.5, µM EGCG, or 0.5 µM PB,
we investigated the ability of SEP co-treatment to modulate the cellular redox state by evaluating GSH
levels with an MCB assay. The effect of the different treatments after 24 h on GSH levels is reported in
Figure 5. All the treatments were able to significantly increase GSH levels in respect to control cells.
In agreement with the viability data, we observed the most effective increase of GSH levels after SEP
co-treatment (1 µM SF, 2.5 µM EGCG, and 0.5 µM PB) in comparison to the single treatment of 1 µM
SF, 2.5 µM EGCG, or 0.5 µM PB.
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Figure 5. Antioxidant activity of SF, EGCG, and PB compounds on SH-SY5Y cells. Cells were
treated with 1 µM SF, 2.5 µM EGCG, and 0.5 µM PB, and after 24 h GSH levels were evaluated
with an monochlorobimane (MCB) assay as reported in Materials and Methods. Data are expressed
as a percentage of untreated cells (CTRL). Each bar represents mean ± SEM of three independent
experiments. Data were analyzed with a one-way ANOVA followed by the Fisher’s test. * p < 0.05 vs.
untreated cells; § p < 0.05 vs. SEP co-treatment.
3.4. SEP Co-Treatment Modulates Genes Involv d in Oxidative Stress Control
As the previous data showed that SEP co-treatment was significantly more effective compared to
the single treatments, we decided to study its ability to modulate cellular antioxidant status. Real-time
PCR analysis was employed to investigate the ability of SEP co-treatment to modulate the mRNA
level of different antioxidant enzymes. The cDNA was obtained from 3D SH-SY5Y cultures that were
co-treated (1 µM SF, 2.5 µM EGCG, and 0.5 µM PB) for 6 h. The 3D cultures were then exposed to
700 µM H2O2 for 1 h prior to lysis (Figure 6). Importantly, SEP co-treatment induced a significant
and marked upregulation of heme oxygenase 1 (HO1), NADPH: qui one oxidoreductase 1 (NQO1),
glutathione reductase (GR), and thioredoxin reductase (TR) in 3D cultures although with different
levels of upregulation (Figure 6). Moreover, SEP co-treat ent in the presence of oxidative stress
induced a significant upregulation of all tested genes in respect to H2O2-treated cells.
NADPH oxidase (NOX) enzymes have been shown to be a major source of ROS in the brain and
to be involved in several neurological diseases [35]. On this basis, we studied the modulatory effect
of SEP co-treatment on NOX1 and NOX2 expression using real-time PCR analysis (Figure 7). In the
absence of oxidative stress, SEP co-treatment had a strong effect on these enzymes as it significantly
reduced NOX1 and NOX2 expression compared to untreated cells. In the presence of oxidative stress
(700 µM H2O2), SEP co-treatment significantly reduced NOX1 and NOX2 expression compared to
H2O2-treated cells. Of note, SEP co-treatment before peroxide exposure maintained NOX1 levels at a
value comparable to control cells.
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Figure 6. Effect of SEP co-treatment on antioxidant enzyme expression. Cells were co-treated with
1 µM SF, 2.5 µM EGCG, and 0.5 µM PB for 6 h. Oxidative stress was induced with 700 µM H2O2 for 1 h
prior to lysis. Real time-PCR was performed to detect heme oxygenase 1 (HO1), NADPH: quinone
oxidoreductase 1 (NQO1), glutathione reductase (GR), and thioredoxin reductase (TR) mRNA levels.
Data are expressed as relative abundance compared to untreated cells. Each bar represents mean ±
SEM of three independent experiments. Data were analyzed with a one-way ANOVA followed by the
Fisher’s test. * p < 0.05 vs. untreated cells, ◦ p < 0.05 vs. H2O2.
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Figure 7. Effect of SEP co-treatment on NADPH oxidase 1 (NOX1) and NADPH oxidase 2 (NOX2). Cells
were co-treated with 1 µM SF, 2.5 µM EGCG, and 0.5 µM PB for 6 h. Oxidative stress was induced with
700 µM H2O2 for 1 h pri r to lysis. Real time- CR was performed to detect NOX1 an NOX2 mRNA
levels. Data are expressed as relative abundance compared to untreated cells. Each bar represents mean
± SEM of three independent experiments. Data were analyzed using a one-way ANOVA followed by
the Fisher’s test. * p < 0.05 vs. untreated cells, ◦ p < 0.05 vs. H2O2.
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3.5. SEP Co-Treatment is able to Modulate Insulin-Degrading Enzyme (IDE) Gene Expression
To investigate if SEP co-treatment had other neuroprotective activities besides the antioxidant
one, we studied its effect on insulin-degrading enzyme (IDE) expression. IDE plays a significant role in
Aβ degradation [36], which is one of the main hallmarks of Alzheimer’s disease. Moreover, recent
studies have demonstrated that increasing Aβ degradation as opposed to inhibiting synthesis is a more
effective strategy for preventing Aβ build-up [37]. In our 3D SH-SY5Y cultures, IDE mRNA levels
were downregulated by oxidative stress, but, interestingly, SEP co-treatment (1 µM SF, 2.5 µM EGCG,
and 0.5 µM PB) was able to upregulate its expression at levels comparable to untreated cells (Figure 8).
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Figure 8. Effect of SEP co-treatment on insulin-degrading enzyme (IDE). Cells were co-treated with
1 µM SF, 2.5 µM EGCG, and 0.5 µM PB for 6 h. Oxidative stress was induced with 700 µM H2O2 for
1 h prior to lysis. Real time-PCR was performed to detect IDE mRNA levels. Data are expressed as
relative abundance compared to untreated cells. Each bar represents mean ± SEM of three independent
experiments. Data were analyzed with a one-way ANOVA followed by the Fisher’s test. * p < 0.05 vs.
untreated cells, ◦ p < 0.05 vs. H2O2.
4. Discussion
The prevalence of neurodegenerative disorders is growing [2,38] in parallel to the urgency to
find new compounds for the treatment of such diseases, in which oxidative stress is a common
hallmark and has been suggested to play a causative role [39,40]. Unfortunately, the screening of drug
leads and natural compounds to counteract neurodegeneration using 2D cell cultures often results in
the unsuccessful translation of data to clinics. Neurons are strongly influenced by their immediate
extracellular environment, and there is a great need to develop new culture systems that more
faithfully reproduce the complexity of this milieu in vivo. Human 3D cell culture models are a good
alternative to animal models [41,42]. In contrast to 2D cell cultures, 3D cell cultures do not overlook
the physical interactions existing between cell–cell and cell–matrix and have a higher resemblance to
the in vivo phenotype. Ideal scaffolds for neuronal tissue or disease modelling should exhibit suitable
3D architecture for in vitro manipulation, should facilitate cell adhesion while promoting neurites
outgrowth, and have high biocompatibility [43]. Collagen type I is highly used as scaffold because of its
abundance and ubiquity in most of the hard and soft tissues in the human body [44]. Porous collagen
sponges have been used to grow various cell types in vitro [45] and collagen derived scaffolds have been
widely used in neural tissue engineering for drug delivery [46]. Furthermore, the extracellular matrix
(ECM) in nerves is mainly composed of type I collagen [47] and is a commonly used material in nerve
tissue engineering [47] and for peripheral nerve regeneration [48]. ECM geometry and composition
are well known to influence cell morphology and gene expression. It has been shown that SH-SY5Y
cells extended longer neurites in 3D collagen I hydrogel cultures than in 2D cultures [26]. On this basis,
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we used equine native collagen, commercially available for clinical application, as scaffold to support
3D cultures of differentiated SH-SY5Y cells.
Our aim was to study the neuroprotective activity of a combination of SF, EGCG, and PB in
counteracting peroxide-induced damage in 3D cultures of differentiated SH-SY5Y cells.
Taking into account previous studies showing the protective effects of these compounds against
oxidative stress [49,50], we decided to treat SH-SY5Y cells with specific concentrations of SF, EGCG,
and PB to better mimic concentrations that could be measured in plasma after oral intake of the three
compounds [51]. We selected a porous instead of a hydrogel scaffold because it easily permits the
removal of apoptotic blebs and dead cells by washing during medium exchange. The used collagenous
scaffold was found to be highly biocompatible since it supported the adhesion and proliferation of
SH-SY5Y cells in the 3D environment.
Our data demonstrated that SEP co-treatment was significantly more effective against oxidative
stress than the single treatments of PB, EGCG, or SF, suggesting a synergistic protective mechanism
of the co-treatment. In particular, SEP was more effective in limiting cell injury induced by H2O2
exposure. These data were also demonstrated in our 2D cell model, and we confirmed the superior
efficacy in enhancing GSH levels by SEP co-treatment compared the single treatments both in 2D
and 3D models (Figure S3). Although different reports have discussed the neuroprotective effect of
PB, EGCG, and SF against brain-induced toxicity [52–54], there is no documented work on the effect
of their combination. Our results are in agreement with other papers demonstrating the synergistic
protective effect of different combinations of natural compounds against neurodegeneration [55–57].
In general, the superior protection of co-treatments compared to the single treatments could be probably
ascribed to the concurrent modulation of different molecular targets involved in the pathogenesis and
progression of these multi-factorial diseases.
To better elucidate the mechanisms behind SEP protection against H2O2 in SH-SY5Y cells,
we investigated the effect of the co-treatment on the expression of different antioxidant enzymes: heme
oxygenase 1 (HO1), NADPH: quinone oxidoreductase 1 (NQO1), glutathione reductase (GR) and
thioredoxin reductase (TR).
The enzyme HO1 converts heme to three end products, namely biliverdin, CO, and ferrous ion [58],
then biliverdin reductase activity produces the antioxidant bilirubin. NQO1 is a highly inducible
detoxifying flavoenzyme. It catalyzes the reduction of quinones generating stable hydroquinones and
possesses superoxide scavenging activity [59]. GR is responsible for maintaining a storage amount
of reduced glutathione [60]. The thioredoxin (Trx) system, composed of Trx, TR, and NADPH as a
cofactor, is a cellular defense system that is ubiquitously involved in converting ROS to nontoxic
metabolites [61]. In such a system, the Trx in reduced status can be oxidized into oxidized Trx during
the degradation of H2O2 and then reduced by TR [62].
SF is known to upregulate antioxidant defense through the induction of HO1, NQO1, and GR
in SH-SY5Y cells [15,63], while GR, TR, and NQO1 have been observed to be upregulated in cortical
neurons [64]. EGCG induced HO1 expression in rat-cultured neurons [65] and increased protein
levels in treated rats following focal cerebral ischemia [66]. PB treatment led to increased levels of
HO1, NQO1, and TR in SH-SY5Y cells [17]. Interestingly, our data showed that SEP co-treatment,
in the absence of oxidative stress, strongly upregulated these enzymes compared to control cells (the
same results were also obtained in the 2D model (Figure S3)), and, in the presence of oxidative stress,
it was able to significantly increase the expression of these enzymes compared to H2O2 exposed cells.
In agreement with our data that showed the enhanced effect of a combination of different compounds
compared to treatment with the single compounds, in a previous work, we observed that a combination
of EGCG and SF counteracts in vitro oxidative stress and delays stemness loss of amniotic fluid stem
cells [67]. Moreover, a combination of berberine with resveratrol had enhanced hypolipidemic effects
in high fat diet-induced mice and was able to decrease the lipid accumulation in adipocytes to a level
significantly lower than that of the treatment with the single compounds [68].
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Recently, it has been suggested that inhibition of the generation, rather than the scavenging, of ROS
may be a more successful strategy to counteract oxidative stress-induced neurodegeneration [69].
ROS can be produced by many enzymes in the cells such as mitochondria respiratory complexes,
NADPH oxidase, nitric oxide synthase, cytochrome 450, cyclooxygenase, lipoxygenase, and xanthine
oxidase [14,70]. Interestingly, all these enzymes except NADPH oxidase produce ROS as a byproduct,
while NOX enzymes generate ROS as a principal aim [71–73]. Moreover, different studies have shown
the involvement of NADPH oxidase family members in brain injury and neurodegenerative disorders
(reviewed in [69]). Our data demonstrated that SEP co-treatment was effective in reducing NOX1 and
NOX2 expression compared to control cells and was also able to counteract the increase of NOX1 and
NOX2 expression induced by H2O2. This means that SEP not only potentiates the antioxidant defense
system upregulating fundamental enzymes, but also reduces the intracellular production of ROS.
The last aim of this paper was to investigate if SEP could modulate other hallmarks of
neurodegeneration in addition to its ability to counteract oxidative stress. We decided to focus
our attention on IDE, the main protease responsible for amyloid β clearance [74–76]. A reduction
of IDE activity in the brain with age and during the early stages of Alzheimer’s disease (AD) has
been observed [74], suggesting that IDE downregulation may be among the triggers of AD. Of note,
SEP counteracted the strong downregulation of IDE induced by oxidative stress, maintaining IDE
expression at a level comparable to control cells, suggesting a potential role of SEP in counteracting AD.
In conclusion, we highlighted that an appropriate synergistic combination of natural antioxidants
such as SF, EGCG, and PB can help to rescue neuronal cells from oxidative stress cell death. The protective
effect of the co-treatment was observed in a novel 3D model of SH-SY5Y cells that we developed.
In agreement with other authors [77–79], we suggest that a 3D culture system better mimics cell–cell
interactions and cell–ECM interactions compared to the traditional 2D monolayer. In particular,
our 3D model would be useful for future investigations of the neuroprotective activity of natural
compounds [80]. In the present study, we observed the protective effect of an “acute” co-treatment
with SF, EGCG, and PB but, taking into account the nature of neurodegeneration, a subchronic/chronic
administration should be even more effective. For this reason, future studies will have to be carried
out to investigate the effect of chronic SEP treatment against oxidative stress in neurodegeneration.
The present findings underscore the importance of a combinatorial approach for effective treatments
against oxidative damage in neurodegeneration. Moreover, 3D SH-SY5Y cell culture systems appear to
be the ideal environment for in vitro assays regarding the effects of phytochemicals on cell viability.
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Figure S1: Visual explanation of MTT assay as used in this study, Figure S2: Cell viability of SH-SY5Y incubated
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SH-SY5Y 3D model.
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Abbreviations
2D Two-dimensional
3D Three-dimensional
BDNF Brain-derived neurotrophic factor
DCFH-DA 2,7-dichlorodihydrofluorescein diacetate
DMEM Dulbecco’s Modified Eagle’s medium
DMSO Dimethyl sulfoxide
ECM Extra cellular matrix
EGCG Epigallocatechin gallate
GR Glutathione reductase
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GSH Reduced glutathione
H2O2 Hydrogen peroxide
HO1 Heme oxygenase 1
IDE Insulin-degrading enzyme
MAP2 Microtubule-associated protein 2
MCB Monochlorobimane
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide)
NOX1 NADPH oxidase 1
NOX2 NADPH oxidase 2
NQO1 NAD(P)H: quinone oxidoreductase 1
PB Plumbagin
PBS Phosphate buffered saline
PCR Polymerase chain reaction
RA All-trans retinoic acid
ROS Reactive oxygen species
RPS18 Ribosomal protein S18
SEP Sulforaphane, Epigallocatechin gallate, Plumbagin
SF Sulforaphane
TR Thioredoxin reductase 1
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